VSTM FY 2024 Earnings — Verastem, Inc. Revenue & Financial Results | Market Cap Arena

VSTMVerastem, Inc.

$388M

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M

Gross Profit

$10M100.0% margin

Operating Income

-$115M-1149.6% margin

Net Income

-$131M-1306.4% margin

EPS (Diluted)

$-3.66

Cash Flow

Operating Cash Flow

-$105M

Free Cash Flow

-$105M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$102M

Total Liabilities

$130M

Stockholders' Equity

-$29M

Cash & Equivalents

$89M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$0	—
Gross Profit	$10M	$0	—
Operating Income	-$115M	-$92M	-24.8%
Net Income	-$131M	-$87M	-49.5%